Business Context and Reporting Period
This Form 8-K reports on events occurring on January 27, 2026, regarding Tempest Therapeutics, Inc. (TPST), a Delaware corporation. The filing details the results of the Company's 2025 Annual Meeting of Stockholders and specific corporate governance actions taken on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance metrics.
Material Changes and Corporate Actions
- Stockholder Rights Plan Extension: Stockholders approved an amendment to the limited duration stockholder rights plan, extending the final expiration date to October 10, 2026.
- Equity Incentive Plan Amendment: Stockholders approved an increase of 1,410,000 shares in the number of common stock shares issuable under the Amended and Restated 2023 Equity Incentive Plan.
- Director Election: Stockholders elected Geoff Nichol as a Class I director to serve until the 2028 Annual Meeting.
- Asset Purchase Agreement Approval: Stockholders approved the issuance of 8,268,495 shares of common stock to satisfy obligations under an Asset Purchase Agreement dated November 19, 2025, with Erigen LLC and Factor Bioscience Inc.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results and Management Commentary
The filing provides final voting results for six proposals submitted at the Annual Meeting. While all proposals were approved, several received significant opposition:
- Proposal 1 (Director Election): Geoff Nichol received 1,003,845 votes for and 599,242 votes withheld.
- Proposal 2 (Say-on-Pay): Approved with 816,856 votes for and 428,524 votes against.
- Proposal 3 (Auditor Ratification): Approved with 1,908,927 votes for and 395,747 votes against.
- Proposal 4 (Rights Plan): Approved with 707,924 votes for and 541,271 votes against.
- Proposal 5 (Stock Issuance): Approved with 1,281,862 votes for and 319,400 votes against.
- Proposal 6 (Equity Plan Amendment): Approved with 646,079 votes for and 600,412 votes against, indicating a closely contested vote.
The filing notes that the Rights Agreement remains unmodified otherwise and is in full force. No specific management commentary regarding future outlook or risks is included in this text.
Investor Verification Checklist
- Verify the terms of the Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc. to understand the context of the 8.27 million share issuance.
- Review the definitive proxy statement filed on December 31, 2025, for detailed rationale behind the Equity Incentive Plan amendment and the Rights Plan extension.
- Monitor the expiration date of the Rights Plan (October 10, 2026) for potential future redemption or exchange events.
- Assess the implications of the high vote-withheld count for the director election and the narrow margin of approval for the Equity Plan amendment.